Insiders who reported open-market trades in the last 12 months at the companies Howard G. Welgus files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
Todd Watanabe - $4.44M in ARQT purchases and sales in the last 12 months
Masaru Matsuda - $2.21M in ARQT purchases and sales in the last 12 months
Patrick Burnett - $1.56M in ARQT purchases and sales in the last 12 months
Keith R. Leonard - $997K in ARQT purchases and sales in the last 12 months
Terrie Curran - $984K in ARQT purchases and sales in the last 12 months
Neha Krishnamohan - $939K in ARQT purchases and sales in the last 12 months
More insiders (A-Z)
Browse nearby insider profiles in alphabetical order.
Howard G. Welgus is a corporate insider, tracked as Director of Arcutis Biotherapeutics, Inc. (ARQT). InsiderAlpha holds 18 primary Form 4 filings for them, the earliest from 2024, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Howard G. Welgus submitted recently?
3 primary Form 4 filings in the last 90 days, covering 1 company.
Has Howard G. Welgus been buying or selling stock?
Recorded transactions: 0 open-market purchases and 20 open-market sales ($2.87M) across all tracked filings.
Howard G. Welgus is Director of Arcutis Biotherapeutics, Inc. (ARQT). 18 SEC Form 4 filings on record going back to 2024, most recently on 17 September 2026. Most recent open-market trade: sold $114K of ARQT on 17 September 2026. Lifetime open-market sales: $2.87M.
Recent transactions
20
The latest 20 SEC Form 4 transactions reported by Howard G. Welgus.
InsiderAlpha's records for Howard G. Welgus go back to 2024: 18 primary Form 4 filings, an average of 6.0 per year. 42 recorded transactions carry a Rule 10b5-1 plan flag. This identifies the marked transactions as reported under a trading plan; it does not establish the plan status of unmarked transactions.
